Bupropion hydrochloride

CLINICAL USE

Adjunct to smoking cessation

DOSE IN NORMAL RENAL FUNCTION

150 mg once daily for 6 days, then twice daily

PHARMACOKINETICS

  • Molecular weight                           :276.2
  • %Protein binding                           :84
  • %Excreted unchanged in urine     : 0.5
  • Volume of distribution (L/kg)       :2000 litres
  • half-life – normal/ESRD (hrs)      :14–20

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : 150 mg daily
  • 10 to 20     : 150 mg daily
  • <10           : 150 mg daily

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in GFR <10 mL/min
  • HD                     :Not dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux   :Not dialysed. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Antidepressants: avoid MAOIs and linezolid with and for 2 weeks before starting treatment; avoid concomitant treatment with moclobemide; possibly increased citalopram concentration
  • Antivirals: concentration increased by ritonavir, risk of toxicity – avoid concomitant use
  • Ciclosporin: may reduce ciclosporin levels

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Bupropion and metabolites may accumulate in renal failure

  • Related News